文献速递糖尿病甲状腺疾病

甲状腺激素对胰岛素受体突变患者葡萄糖处置的影响

Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本研究为单臂开放标签试验,评估三碘甲状腺原氨酸(liothyronine)对胰岛素受体(INSR)突变患者血糖的影响。7例患者接受2周治疗,其中4例HbA1c>7%者延长至6个月。结果显示2周时全身、肌肉及白色脂肪组织葡萄糖摄取无变化;6个月时HbA1c无显著改善,但全身葡萄糖处置、肌肉及白色脂肪组织葡萄糖摄取显著增加。

要点

  • 三碘甲状腺原氨酸耐受剂量未改善INSR突变患者的HbA1c。
  • 6个月治疗可增加全身、肌肉及白色脂肪组织葡萄糖摄取。
  • 棕色脂肪组织葡萄糖摄取因体积小无法定量。

核心结论

  • 三碘甲状腺原氨酸在耐受剂量下未改善HbA1c,但观察到的肌肉和白色脂肪组织葡萄糖摄取增加支持其增加组织葡萄糖摄取的机制。

研究设计与样本

  • 单臂、开放标签的三碘甲状腺原氨酸研究,共纳入7例INSR突变患者(纯合子5例,杂合子2例)。
  • 干预为每8小时一次三碘甲状腺原氨酸治疗2周(n=7),HbA1c>7%者额外治疗6个月(n=4)。

主要发现

  • 2周治疗前后,全身、肌肉及白色脂肪组织葡萄糖摄取无变化。
  • 6个月后,HbA1c无显著变化(8.3 ± 1.2 vs 9.1 ± 3.0%,P = 0.27)。
  • 6个月后,全身葡萄糖处置增加(22.8 ± 4.9 vs 30.1 ± 10.0 µmol/kg lean body mass/min,P = 0.02)。
  • 6个月后,肌肉葡萄糖摄取增加(0.7 ± 0.1 vs 2.0 ± 0.2 µmol/min/100 mL,P < 0.0001)。
  • 6个月后,白色脂肪组织葡萄糖摄取增加(1.2 ± 0.2 vs 2.2 ± 0.3 µmol/min/100 mL,P < 0.0001)。

临床怎么用

  • 对于INSR突变患者,三碘甲状腺原氨酸虽未改善HbA1c,但可能增加组织葡萄糖摄取,提示更选择性药物或可避免甲状腺激素相关全身毒性。

局限性

  • 棕色脂肪组织葡萄糖摄取因体积小无法定量。
  • 研究为单臂开放标签设计,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with mutations of the insulin receptor gene (INSR) have extreme insulin resistance and are at risk for early morbidity and mortality from diabetes complications. A case report suggested that thyroid hormone could improve glycemia in INSR mutation in part by increasing brown adipose tissue (BAT) activity and volume. OBJECTIVE: To determine if thyroid hormone increases tissue glucose uptake and improves hyperglycemia in INSR mutation. DESIGN: Single-arm, open-label study of liothyronine. SETTING: National Institutes of Health. PARTICIPANTS: Patients with homozygous (n = 5) or heterozygous (n = 2) INSR mutation. INTERVENTION: Liothyronine every 8 hours for 2 weeks (n = 7); additional 6 months' treatment in those with hemoglobin A1c (HbA1c) > 7% (n = 4). OUTCOMES: Whole-body glucose uptake by isotopic tracers; tissue glucose uptake in muscle, white adipose tissue (WAT) and BAT by dynamic [18F] fluorodeoxyglucose positron emission tomography/computed tomography; HbA1c. RESULTS: There was no change in whole-body, muscle, or WAT glucose uptake from baseline to 2 weeks of liothyronine. After 6 months, there was no change in HbA1c (8.3 ± 1.2 vs 9.1 ± 3.0%, P = 0.27), but there was increased whole-body glucose disposal (22.8 ± 4.9 vs 30.1 ± 10.0 µmol/kg lean body mass/min, P = 0.02), and muscle (0.7 ± 0.1 vs 2.0 ± 0.2 µmol/min/100 mL, P < 0.0001) and WAT glucose uptake (1.2 ± 0.2 vs 2.2 ± 0.3 µmol/min/100 mL, P < 0.0001). BAT glucose uptake could not be quantified because of small volume. There were no signs or symptoms of hyperthyroidism. CONCLUSION: Liothyronine administered at well-tolerated doses did not improve HbA1c. However, the observed increases in muscle and WAT glucose uptake support the proposed mechanism that liothyronine increases tissue glucose uptake. More selective agents may be effective at increasing tissue glucose uptake without thyroid hormone-related systemic toxicity.Clinical Trial Registration Number: NCT02457897; https://clinicaltrials.gov/ct2/show/NCT02457897.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kushchayeva YS, Startzell M, Cochran E, et al. Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations. J Clin Endocrinol Metab. 2020. PMID: 31588494. doi:10.1210/clinem/dgz079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。